Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact

Editorials

  • 233 Articles
  • 0 Posts
  • ← Previous
  • 1
  • 2
  • 3
  • 4
  • …
  • 23
  • 24
  • Next →
Clinical medicine
Howard A. Rockman
Howard A. Rockman
Published December 3, 2012
Citation Information: J Clin Invest. 2012;122(12):4303-4303. https://doi.org/10.1172/JCI67619.
View: Text | PDF

Clinical medicine

  • Text
  • PDF
Abstract

With the December issue of the Journal of Clinical Investigation, I announce the launch of a new category of manuscript called “Clinical Medicine,” along with new editorial board members to adjudicate the peer-review process. With this initiative, the journal aims to publish the highest quality human research that reports early-stage, effective new therapies that impact disease outcomes.

Authors

Howard A. Rockman

×

Constitutively, pathologically, profoundly
Ushma S. Neill
Ushma S. Neill
Published May 1, 2012
Citation Information: J Clin Invest. 2012;122(5):1585-1585. https://doi.org/10.1172/JCI64042.
View: Text | PDF

Constitutively, pathologically, profoundly

  • Text
  • PDF
Abstract

There are a hundred reasons to love the JCI and I have loved it truly, madly, and deeply for the last nine years. Alas, I’ll have to learn to love the Journal from afar, as tomorrow marks my last official day as Executive Editor. To quote Chaucer, “There is an end to everything, to good things as well.”

Authors

Ushma S. Neill

×

Great expectations
Howard A. Rockman
Howard A. Rockman
Published April 2, 2012
Citation Information: J Clin Invest. 2012;122(4):1133-1133. https://doi.org/10.1172/JCI63462.
View: Text | PDF

Great expectations

  • Text
  • PDF
Abstract

On the occasion of the 200th anniversary of Charles Dickens’s birth, I am struck by his creative genius and by the parallel between the intellectual development of his protagonists and the evolution of peer review. Like many of his novels and serial writings, the story of the history of peer review is a bildungsroman, one that has followed a process of growing up, sought answers through a journey marked by achievement and disappointment, and ultimately matured to be accepted by a community.

Authors

Howard A. Rockman

×

Tradition, tradition
Howard A. Rockman
Howard A. Rockman
Published March 1, 2012
Citation Information: J Clin Invest. 2012;122(3):785-786. https://doi.org/10.1172/JCI63105.
View: Text | PDF

Tradition, tradition

  • Text
  • PDF
Abstract

Starting with this issue, the Editorial duties for the JCI move to Duke University and the University of North Carolina at Chapel Hill. As we begin our five-year tenure at the helm of this prestigious journal, the tradition of excellence that these two schools typically display on the basketball court now enters the editorial boardroom.

Authors

Howard A. Rockman

×

Plus ça change, plus c’est la même chose
Laurence A. Turka
Laurence A. Turka
Published February 1, 2012
Citation Information: J Clin Invest. 2012;122(2):422-423. https://doi.org/10.1172/JCI62577.
View: Text | PDF

Plus ça change, plus c’est la même chose

  • Text
  • PDF
Abstract

Authors

Laurence A. Turka

×

Editorial position on publishing articles on human organ transplantation
Arthur L. Caplan, … , Howard A. Rockman, Laurence A. Turka
Arthur L. Caplan, … , Howard A. Rockman, Laurence A. Turka
Published January 3, 2012
Citation Information: J Clin Invest. 2012;122(1):2-2. https://doi.org/10.1172/JCI61904.
View: Text | PDF

Editorial position on publishing articles on human organ transplantation

  • Text
  • PDF
Abstract

The practice of transplanting organs from executed prisoners in China appears to be widespread. We vigorously condemn this practice and, effective immediately, will not consider manuscripts on human organ transplantation for publication unless appropriate non-coerced consent of the donor is provided and substantiated.

Authors

Arthur L. Caplan, Howard A. Rockman, Laurence A. Turka

×

Politicizing NIH funding: a bridge to nowhere
Jonathan A. Epstein
Jonathan A. Epstein
Published September 1, 2011
Citation Information: J Clin Invest. 2011;121(9):3362-3363. https://doi.org/10.1172/JCI60182.
View: Text | PDF

Politicizing NIH funding: a bridge to nowhere

  • Text
  • PDF
Abstract

We live in a time of increased spending, mounting debt, and few remedies for balancing the federal budget that have bipartisan support. Unfortunately, one recent target for decreased allocations of the federal budget is the NIH; the discussion of the awarded grants and the grant funding process has been skewed and altered to present medical research in an unfriendly light, and this can have very damaging repercussions. Politicizing this process could ultimately challenge human health, technology, and economic growth.

Authors

Jonathan A. Epstein

×

You know what we need?
Ushma S. Neill
Ushma S. Neill
Published August 1, 2011
Citation Information: J Clin Invest. 2011;121(8):2948-2948. https://doi.org/10.1172/JCI59681.
View: Text | PDF

You know what we need?

  • Text
  • PDF
Abstract

I’ve listened to many of you moan about the current flat NIH budgets, lack of funding, and the frustration of being a scientist in the current depressed economy. Instead of complaining to only ourselves in the scientific community, we need to make ourselves heard by politicians and the public at large. We need a pundit.

Authors

Ushma S. Neill

×

What is the evidence for our standards of care?
Laurence A. Turka, Arthur Caplan
Laurence A. Turka, Arthur Caplan
Published July 1, 2011
Citation Information: J Clin Invest. 2011;121(7):2530-2530. https://doi.org/10.1172/JCI59185.
View: Text | PDF

What is the evidence for our standards of care?

  • Text
  • PDF
Abstract

The term evidence-based medicine is overused, abused, and is beginning to ring hollow. It is not that evidence (or at least of what most people in biomedicine think evidence-based medicine should strive to be) is a bad thing. Rather, there is more rhetoric about evidence than there is actual evidence to support the degree of talk.

Authors

Laurence A. Turka, Arthur Caplan

×

Enhancing discovery and saving money with MERIT
Jonathan A. Epstein
Jonathan A. Epstein
Published April 1, 2011
Citation Information: J Clin Invest. 2011;121(4):1226-1226. https://doi.org/10.1172/JCI57708.
View: Text | PDF

Enhancing discovery and saving money with MERIT

  • Text
  • PDF
Abstract

The National Institutes of Health and many of our biomedical institutions face significant budgetary challenges that are likely to persist for the foreseeable future. The paylines for Research Project Grant (RO1) applications to the NIH will be near or below the tenth percentile, and many investigators are growing increasingly concerned about maintaining their research programs. One of the most concerning potential results of limited grant dollars is the natural tendency for researchers to propose conservative projects that are more likely to succeed, to do well in peer review, and to be funded, but that may not dramatically advance the field, and a concurrent tendency among study sections to reward proposals that are seen as safe, if uninspiring. Established and well-respected investigators may be (perhaps appropriately) given the benefit of the doubt when compared with less-established colleagues and may therefore command a growing percentage of the total available grant dollars, while simultaneously avoiding bold and potentially groundbreaking approaches. At the same time, fewer dollars are available for new investigators with unproven track records and for the expansion of newly successful programs.

Authors

Jonathan A. Epstein

×
  • ← Previous
  • 1
  • 2
  • 3
  • 4
  • …
  • 23
  • 24
  • Next →

No posts were found with this tag.

Advertisement

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts